Phase Ib/II trial of pembrolizumab (pembro) plus lenvatinib combination therapy in patients (pts) with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE): KEYNOTE-365 cohorts E and F

被引：0

作者：

Kramer, G. ^{[1
]}

Shore, N. D. ^{[2
]}

Joshua, A. M. ^{[3
]}

Li, X. T. ^{[4
]}

Poehlein, C. H. ^{[4
]}

Schloss, C. ^{[4
]}

de Bono, J. S. ^{[5
]}

Yu, E. ^{[6
]}

机构：

[1] Med Univ Vienna, Urol, Vienna, Austria

[2] Carolina Urol Res Ctr, Urol, Myrtle Beach, SC USA

[3] St Vincents Hosp Sydney, Med Oncol, Sydney, NSW, Australia

[4] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA

[5] Royal Marsden NHS Fdn Trust, Med Oncol, London, England

[6] Univ Washington, Med Oncol, Seattle, WA 98195 USA

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.1153

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

640TiP

引用

页码：S669 / S670

页数：2

共 50 条

[31] KEYNOTE-365 cohort C updated results: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
Berry, William R.
Fong, Peter C. C.
Piulats, Josep M.
Appleman, Leonard Joseph
Conter, Henry Jacob
Feyerabend, Susan
Shore, Neal D.
Gravis, Gwenaelle
Laguerre, Brigitte
Gurney, Howard
Retz, Margitta
Romano, Emanuela
Mourey, Loic
De Bono, Johann S.
Kam, Audrey E.
Emmenegger, Urban
Wu, Helen
Schloss, Charles
Poehlein, Christian Heinrich
Yu, Evan Y.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[32] Pembrolizumab (pembro) plus olaparib in patients with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Update of KEYNOTE-365 cohort A with a minimum of 11 months of follow-up for all patients
Yu, E.
Piulats, J. M.
Gravis, G.
Fong, P. C. C.
Todenhoefer, T.
Laguerre, B.
Arranz Arija, J. A.
Oudard, S.
Massard, C.
Stoeckle, M.
Nordquist, L. T.
Carles, J.
Kolinsky, M. P.
Augustin, M.
Gurney, H.
Tafreshi, A.
Li, X. T.
Poehlein, C. H.
Schloss, C.
de Bono, J. S.
ANNALS OF ONCOLOGY, 2021, 32 : S652 - S653
[33] Pembrolizumab (pembro) plus enzalutamide (enza) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Randomized double-blind phase III KEYNOTE-641 study
Graff, J. N.
Burotto, M.
Fong, P. C.
Pook, D.
Zurawski, B.
Kopp, R. Manneh
Salinas, J. E.
Bylow, K.
Kramer, G.
Ratta, R.
Kwiatkowski, M.
Retz, M.
Kwak, C.
Arija, J. A. Arranz
Gurney, H. P.
Matsubara, N.
Liang, L. W.
Todoric, J.
Imai, K.
Stenzl, A.
ANNALS OF ONCOLOGY, 2023, 34 : S957 - S957
[34] Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort A of the phase 1b/2 KEYNOTE-365 study.
Yu, Evan Y.
Massard, Christophe
Retz, Margitta
Tafreshi, Ali
Carles, Joan
Hammerer, Peter
Fong, Peter C. C.
Shore, Neal D.
Joshua, Anthony M.
Linch, Mark David
Gurney, Howard
Romano, Emanuela
Augustin, Marinela
Piulats, Josep M.
Wu, Helen
Schloss, Charles
Poehlein, Christian Heinrich
De Bono, Johann S.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[35] Phase II study of pembrolizumab (pembro) plus enzalutamide for enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update from KEYNOTE-199
Vaishampayan, U. N.
Elliott, T.
Omlin, A. G.
Graff, J. N.
Hoimes, C. J.
Tagawa, S. T.
Hwang, C.
Kilari, D.
Ten Tije, A. J.
McDermott, R. S.
Gerritsen, W. R.
Wu, H.
Kim, J.
Schloss, C.
de Bono, J. S.
Antonarakis, E. S.
ANNALS OF ONCOLOGY, 2020, 31 : S1330 - S1330
[36] Pembrolizumab Combination Therapies in Patients With Metastatic Castration-Resistant Prostate Cancer: Cohorts A-C of the Phase 1b/2 KEYNOTE-365 Study
Joshua, Anthony M.
Gurney, Howard
Retz, Margitta
Tafreshi, Ali
Fong, Peter
Shore, Neal
Romano, Emanuela
Augustin, Marinela
Piulats, Josep M.
Berry, William R.
Kolinsky, Michael Paul
Sridhar, Srikala S.
Conter, Henry Joacob
Todenhofer, Tilman
Appleman, Leonard J.
Wu, Haiyan
Schloss, Charles
Poehlein, Christian Heinrich
de Bono, Johann S.
Yu, Evan Y.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 46 - 47
[37] KEYNOTE-921: Phase III study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone (abi)-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Petrylak, D. P.
Li, B.
Schloss, C.
Fizazi, K.
ANNALS OF ONCOLOGY, 2019, 30 : 351 - 351
[38] Two-year follow-up of KEYNOTE-365 cohort D: Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)
Linch, M.
Ferrario, C.
Stoeckle, M.
Laguerre, B.
Arija, J. A. Arranz
Todenhofer, T.
Fong, P. C.
Rodriguez, J. M. Piulats
Berry, W.
Emmenegger, U.
Mourey, L.
Mar, N.
Appleman, L. J.
Joshua, A.
Conter, H. J.
Li, X. T.
Schloss, C.
Poehlein, C. H.
de Bono, J. S.
Yu, E. Y.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1178 - S1178
[39] Phase III study of pembrolizumab (pembro) plus enzalutamide (enza) versus placebo plus enza for metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-641
Graff, Julie Nicole
Burgents, Joseph
Liang, Li Wen
Stenzl, Arnulf
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[40] PEMBROLIZUMAB (PEMBRO) PLUS OLAPARIB IN PATIENTS WITH DOCETAXEL-PRETREATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): UPDATED RESULTS FROM KEYNOTE-365 COHORT A WITH A MINIMUM OF 11 MONTHS OF FOLLOW-UP FOR ALL PATIENTS
Nordquist, Luke T.
Yu, Evan Y.
Piulats, Josep M.
Gravis, Gwenaelle
Fong, Peter C. C.
Todenhoefer, Tilman
Laguerre, Brigitte
Arranz Arija, Jose Angel
Oudard, Stephane
Massard, Christophe
Stoeckle, Michael
Carles, Joan
Kolinsky, Michael Paul
Augustin, Marinela
Gurney, Howard
Tafreshi, Ali
Li, Xin Tong
Poehlein, Christian Heinrich
Schloss, Charles
de Bono, Johann S.
JOURNAL OF UROLOGY, 2021, 206 : E417 - E417

← 1 2 3 4 5 →